Chemoselection of Allogeneic HSC After Murine Neonatal Transplantation Without Myeloablation or Post-transplant Immunosuppression

Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
Molecular Therapy (Impact Factor: 6.23). 08/2012; 20(11). DOI: 10.1038/mt.2012.136
Source: PubMed


The feasibility of allogeneic transplantation, without myeloablation or post-transplant immunosuppression, was tested using in vivo chemoselection of allogeneic hematopoietic stem cells (HSCs) after transduction with a novel tricistronic lentiviral vector (MGMT(P140K)-2A-GFP-IRES-TK (MAGIT)). This vector contains P140K-O(6)-methylguanine-methyltransferase (MGMT(P140K)), HSV-thymidine kinase (TK(HSV)), and enhanced green fluorescent protein (eGFP) enabling (i) in vivo chemoselection of HSC by conferring resistance to benzylguanine (BG), an inhibitor of endogenous MGMT, and to chloroethylating agents such as 1,3-bis(2-chloroethyl)nitrosourea (BCNU) and, (ii) depletion of proliferating cells such as malignant clones or transduced donor T cells mediating graft versus host disease (GVHD), by expression of the suicide gene TK(HSV) and Ganciclovir (GCV) administration. Non-myeloablative transplantation of transduced, syngeneic, lineage-depleted (Lin(-)) BM in neonates resulted in 0.67% GFP(+) mononuclear cells in peripheral blood. BG/BCNU chemoselection, 4 and 8 weeks post-transplant, produced 50-fold donor cell enrichment. Transplantation and chemoselection of major histocompatibility complex (MHC)-mismatched MAGIT-transduced Lin(-) BM also produced similar expansion for >40 weeks. The efficacy of this allotransplant approach was validated in Hbb(th3) heterozygous mice by correction of β-thalassemia intermedia, without toxicity or GVHD. Negative selection, by administration of GCV resulted in donor cell depletion without graft ablation, as re-expansion of donor cells was achieved with BG/BCNU treatment. These studies show promise for developing non-ablative allotransplant approaches using in vivo positive/negative selection.

Download full-text


Available from: Stanton L Gerson, Mar 23, 2014
  • Source
    • "Studies aimed at coupling selective stem cell enrichment to therapeutic gene expression have focused on the use of dual-gene vectors (Persons et al., 2003; Falahati et al., 2012; Richard et al., 2004; Trobridge et al., 2009). Many strategies have been employed to co-express two genes from the same vector, including the use of alternative splice sites, internal promoters, gene fusions, IRES elements , and ribosome slippage sites (Morgan et al., 1992; Sugimoto et al., 1994; de Felipe et al., 1999; Klump et al., 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The DNA repair gene O(6)-methylguanine-DNA methyltransferase (MGMT) allows efficient in vivo enrichment of transduced hematopoietic stem cells (HSC). Thus, linking this selection strategy to therapeutic gene expression offers the potential to reconstitute diseased hematopoietic tissue with gene-corrected cells. However, different dual-gene expression vector strategies are limited by poor expression of one or both transgenes. To evaluate different co-expression strategies in the context of MGMT-mediated HSC enrichment, we compared selection and expression efficacies in cells cotransduced with separate single-gene MGMT and GFP lentivectors to those obtained with dual-gene vectors employing either encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) or foot and mouth disease virus (FMDV) 2A elements for co-expression strategies. Each strategy was evaluated in vitro and in vivo using equivalent multiplicities of infection (MOI) to transduce 5-fluorouracil (5-FU) or Lin(-)Sca-1(+)c-kit(+) (LSK)-enriched murine bone marrow cells (BMCs). The highest dual-gene expression (MGMT(+)GFP(+)) percentages were obtained with the FMDV-2A dual-gene vector, but half of the resulting gene products existed as fusion proteins. Following selection, dual-gene expression percentages in single-gene vector cotransduced and dual-gene vector transduced populations were similar. Equivalent MGMT expression levels were obtained with each strategy, but GFP expression levels derived from the IRES dual-gene vector were significantly lower. In mice, vector-insertion averages were similar among cells enriched after dual-gene vectors and those cotransduced with single-gene vectors. These data demonstrate the limitations and advantages of each strategy in the context of MGMT-mediated selection, and may provide insights into vector design with respect to a particular therapeutic gene or hematologic defect. Copyright © 2014. Published by Elsevier B.V.
    Full-text · Article · Dec 2014 · Virus Research
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mucopolysaccharidosis type II (MPS II) is a neuropathic lysosomal storage disorder caused by the iduronate-2-sulfatase (IDS) deficiency, which leads to accumulation of glycosaminoglycans (GAGs). Recently, we demonstrated that biochemical alterations in brains from MPS II mice are not corrected by bone marrow transplantation (BMT) as well as enzyme replacement therapy, whereas BMT has been shown to be effective for other neurodegenerative MPS such as Hurler syndrome. In this study, we show that lentiviral isogeneic hematopoietic stem cell (HSC) gene therapy corrects the neuronal manifestation through the amelioration of lysosomal storages and autophagic dysfunctions in brains from MPS II mice. IDS-transduced HSCs provided the increased enzyme activity not only in a variety of viscera, but also in central nervous system (CNS). Decreased levels of GAGs were also observed in multiple organs including cerebrum after transplantation of IDS-transduced HSCs. In addition, lentiviral HSC gene therapy normalized the secondary accumulation of autophagic substrates such as p62 and ubiquitin-protein conjugates in the cerebrums. Furthermore, deterioration of neuronal function was not observed in transplanted recipient in contrast with naïve MPS II mice. These results indicate that lentiviral HSC gene therapy is a promising approach for the treatment of CNS lesions in MPS II.
    Full-text · Article · Mar 2015 · Human Gene Therapy
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Substantial advances have been made in the past two decades in the management of osteoporosis. However, none of the current medications can eliminate the risk of fracture and rejuvenate the skeleton. To this end, we recently reported that transplantation of hematopoietic stem/progenitor cells (HSCs) or Sca1(+) cells engineered to overexpress FGF2 results in a significant increase in lamellar bone matrix formation at the endosteum; but this increase was attended by the development of secondary hyperparathyroidism and severe osteomalacia. Here we switch the therapeutic gene to PDGFB, another potent mitogen for mesenchymal stem cells (MSCs) but potentially safer than FGF2. We found that modest overexpression of PDGFB using a relatively weak phosphoglycerate kinase (PGK) promoter completely avoided osteomalacia and secondary hyperparathyroidism, and simultaneously increased trabecular bone formation and trabecular connectivity, and decreased cortical porosity. These effects led to a 45% increase in the bone strength. Transplantation of PGK-PDGFB-transduced Sca1(+) cells increased MSC proliferation, raising the possibility that PDGF-BB enhances expansion of MSC in the vicinity of the hematopoietic niche where the osteogenic milieu propels the differentiation of MSCs toward an osteogenic destination. Our therapy should have potential clinical applications for patients undergoing HSC transplantation, who are at high risk for osteoporosis and bone fractures after total body irradiation preconditioning. It could eventually have wider application once the therapy can be applied without the preconditioning.
    Full-text · Article · Jul 2015 · Proceedings of the National Academy of Sciences